How to Help Your Patients Save Money on Qbrexza: A Provider's Guide to Savings Programs

Qbrexza (glycopyrronium cloth, 2.4%) is an effective, FDA-approved treatment for primary axillary hyperhidrosis — but with an average retail cash price of $840–$939 for a 30-day supply, cost is one of the primary drivers of prescription abandonment. Studies consistently show that patients who experience sticker shock at the pharmacy often simply do not fill their prescription, even when their condition significantly impacts quality of life.

As a prescriber, you have significant power to prevent this outcome. By understanding the Qbrexza savings landscape and building it into your prescribing workflow, you can dramatically improve treatment initiation and adherence for your hyperhidrosis patients. This guide covers every savings program available in 2026 and practical steps to make sure your patients can access them.

Understanding the Qbrexza Cost Landscape

Before reviewing savings options, it's useful to understand why Qbrexza is expensive. It is a brand-name-only medication — no generic equivalent exists as of 2026. Without market competition from generics, the manufacturer controls pricing. Additionally:

• Medicare Part D typically does not cover Qbrexza
• Many commercial plans require prior authorization, and some deny coverage entirely
• Step therapy requirements may delay access for patients who haven't yet tried aluminum chloride antiperspirants
• The Journey Total Access Program — though generous — routes patients to a limited network of pharmacies, adding friction to the fill process

Program 1: Journey Total Access Program (Best for Commercially Insured Patients)

The Journey Total Access Program is Journey Medical Corporation's primary savings program. For eligible patients:

• Commercially insured patients filling at in-network pharmacies pay as little as $0 (insurance covers Qbrexza) or no more than $50 (insurance does not cover it)
• No savings card is required at in-network pharmacies
• Some in-network pharmacies offer direct-to-patient shipping

Action for providers: Direct patients to the pharmacy locator at getqbrexza.com before or at the point of prescribing. Consider routing your e-prescribing directly to an in-network pharmacy — this can be arranged by checking the locator during the office visit. Your MA or care coordinator can build this step into your Qbrexza prescribing workflow.

Eligibility restrictions: Not valid for Medicare, Medicaid, TRICARE, VA, or other government-funded healthcare programs. Valid only in the United States. Maximum reimbursement limits apply.

Program 2: Qbrexza Patient Savings Card (Out-of-Network Pharmacies)

For commercially insured patients whose insurance covers Qbrexza on some level but who prefer an out-of-network pharmacy, the Qbrexza Patient Savings Card is available for download at getqbrexza.com. When combined with insurance, the savings card may allow the patient to pay as little as $0.

Action for providers: Print savings card information or provide the URL to patients at the point of prescribing. Clarify to patients that the savings card only applies if their insurance covers Qbrexza — if insurance doesn't cover it at all, the card will not help at an out-of-network pharmacy.

Program 3: Patient Assistance Program

Journey Medical Corporation may offer patient assistance for uninsured patients or those whose insurance has denied Qbrexza and who meet income-eligibility criteria. This program typically requires:

• Completed application from the patient
• Proof of income (typically federal income tax return or equivalent)
• Prescriber signature and documentation of diagnosis

Action for providers: Have your MA or patient navigator contact Journey Medical patient support at 1-855-531-1859 to verify current eligibility requirements and obtain application materials. Processing time and eligibility criteria may change — confirm current status with the manufacturer.

Program 4: GoodRx and Third-Party Coupon Programs

For patients who are on Medicare, Medicaid, or have commercial insurance that doesn't cover Qbrexza and who are paying cash, GoodRx and similar platforms offer the next best savings tier:

• GoodRx: Reduces Qbrexza to approximately $630.92/month at participating pharmacies
• SingleCare: Reduces Qbrexza to approximately $653/month at pharmacies including Walmart, Walgreens, Kroger, and Harris Teeter

Action for providers: GoodRx coupons cannot be combined with insurance. However, for Medicare patients or those with non-covering plans, GoodRx/SingleCare are the most accessible savings tools. Consider directing patients to goodrx.com or printing a coupon from your office EHR (many EHR platforms now integrate GoodRx coupon generation directly into the prescribing workflow).

Optimizing Prior Authorization for Qbrexza

A successful PA approval can unlock commercial insurance coverage, which in turn enables the Journey Total Access Program. High-yield PA documentation strategies:

• Use ICD-10 code L74.510 (primary focal hyperhidrosis, axilla)
• Document HDSS score (a validated 4-item severity scale) in your clinical note
• Document inadequate response to prescription aluminum chloride antiperspirant (step therapy trigger for most plans)
• Include quality-of-life language: e.g., 'Patient reports significant impact on occupational performance and social interactions due to visible sweating despite prior treatment'
• Use plan-specific PA forms — Journey Medical (1-855-531-1859) can supply these and may assist with tracking submission status

When Qbrexza Remains Inaccessible: Cost-Effective Alternatives

When all savings programs are exhausted or inapplicable (particularly for Medicare patients), consider these cost-effective alternatives:

• Oral glycopyrrolate generic: $15–$30/month; same mechanism, higher systemic side effect burden
• Prescription aluminum chloride (Drysol): Affordable, broadly covered, well-established; appropriate for mild to moderate cases
• Botox (onabotulinumtoxinA) with insurance: FDA-approved for axillary hyperhidrosis; Medicare coverage may be available with appropriate prior authorization; treatment every 4–6 months

For providers who want to refer patients to a resource that helps them find Qbrexza at pharmacies near them, medfinder calls pharmacies on the patient's behalf and texts them results. This can reduce the number of pharmacy-related calls your office receives. See also our companion guide on Qbrexza availability for providers in 2026.